MarketCap
Facebook
X
Telegram
Bellicum Pharmaceuticals Operating Cycle | BLCM
Annual Operating Cycle Bellicum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.9 | 6.09 | 111 | 31 | 719 | -1.73 K | 364 | 478 | 30.5 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 719 | -1.73 K | 3.85 |
Quarterly Operating Cycle Bellicum Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 45.6 | - | 55.2 | - | - | - | 13.3 | 83.4 | - | - | - | - | - | 5.39 | 268 | 19.9 | 107 | 266 | 284 | 229 | 364 | -423 | 232 | - | 233 | 376 | 267 | 302 | 384 | 1.18 K | 704 | 239 | 127 | 906 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 K | -423 | 261 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioXcel Therapeutics
BTAI
|
1.66 K | $ 0.07 | 9.81 % | $ 855 K |  USA |
 |
Navidea Biopharmaceuticals
NAVB
|
54.7 K | - | -2.99 % | $ 2.47 M | USA |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
Insmed Incorporated
INSM
|
400 | $ 120.63 | 0.95 % | $ 24 B | USA |
 |
Novan
NOVN
|
234 | - | -24.84 % | $ 2.64 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
bluebird bio
BLUE
|
180 | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
257 | - | - | $ 13.6 B | USA |
 |
Marinus Pharmaceuticals
MRNS
|
59.8 | - | - | $ 29.6 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-65.8 | - | -1.56 % | $ 12.3 M | USA |
 |
CASI Pharmaceuticals
CASI
|
189 | - | - | $ 35.4 M | USA |
 |
Sigilon Therapeutics
SGTX
|
31.4 | - | - | $ 728 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Revance Therapeutics
RVNC
|
30.4 | - | - | $ 309 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
492 | $ 4.86 | 1.04 % | $ 787 M | USA |
 |
Epizyme
EPZM
|
47.2 | - | - | $ 249 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
8.16 K | - | -6.81 % | $ 3.04 B | USA |
 |
Nabriva Therapeutics plc
NBRV
|
214 | - | - | $ 4.55 M |  Irlanda |
 |
NGM Biopharmaceuticals
NGM
|
18.4 | - | - | $ 127 M | USA |
 |
9 Meters Biopharma
NMTR
|
111 | - | -42.97 % | $ 1.05 M | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Theratechnologies
THTX
|
456 | - | - | $ 83.9 M |  Canada |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
scPharmaceuticals
SCPH
|
447 | - | - | $ 218 M | USA |
 |
Athersys
ATHX
|
73 | - | 3.77 % | $ 22.4 M | USA |
 |
Liquidia Corporation
LQDA
|
36.8 | $ 55.17 | 7.32 % | $ 4.75 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
361 | $ 317.17 | 0.96 % | $ 6.13 B | USA |
 |
Global Blood Therapeutics
GBT
|
5.46 K | - | - | $ 4.62 B | USA |
 |
MannKind Corporation
MNKD
|
457 | $ 4.18 | -1.3 % | $ 1.28 B | USA |
 |
Merck & Co.
MRK
|
204 | $ 147.17 | -0.57 % | $ 368 B | USA |
 |
NanoString Technologies
NSTG
|
311 | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
598 | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
125 | - | -29.58 % | $ 126 M | USA |